{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05379101",
            "orgStudyIdInfo": {
                "id": "22-001098"
            },
            "organization": {
                "fullName": "Mayo Clinic",
                "class": "OTHER"
            },
            "briefTitle": "Intracardiac Flow Assessment in Cardiac Amyloidosis",
            "officialTitle": "Intracardiac Flow Assessment in Cardiac Amyloidosis",
            "therapeuticArea": [
                "Cardiovascular",
                "Other"
            ],
            "study": "intracardiac-flow-assessment-in-cardiac-amyloidosis"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-07-20",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-05-13",
            "studyFirstSubmitQcDate": "2022-05-13",
            "studyFirstPostDateStruct": {
                "date": "2022-05-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-02",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Ian C. Chang",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Mayo Clinic"
            },
            "leadSponsor": {
                "name": "Mayo Clinic",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The primary objective of this study is to define the intracardiac flow imaging biomarkers in cardiac amyloidosis."
        },
        "conditionsModule": {
            "conditions": [
                "Amyloidosis Cardiac",
                "Healthy Adults"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "CASE_CONTROL",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Transthyretin (ATTR) cardiac amyloidosis",
                    "description": "Subjects diagnosed with ATTR cardiac amyloidosis will have CMR, TTE, and 6-minute walk",
                    "interventionNames": [
                        "Diagnostic Test: Cardiac magnetic resonance image (CMR)",
                        "Diagnostic Test: Transthoracic Echocardiogram (TTE)",
                        "Diagnostic Test: Six-minute Walk Test"
                    ]
                },
                {
                    "label": "Light chain amyloidosis (AL) with cardiac involvement",
                    "description": "Subjects diagnosed with AL with cardiac involvement will have CMR, TTE, and 6-minute walk",
                    "interventionNames": [
                        "Diagnostic Test: Cardiac magnetic resonance image (CMR)",
                        "Diagnostic Test: Transthoracic Echocardiogram (TTE)",
                        "Diagnostic Test: Six-minute Walk Test"
                    ]
                },
                {
                    "label": "Light chain amyloidosis (AL) without cardiac involvement",
                    "description": "Subjects diagnosed with AL without cardiac involvement will have CMR, TTE, and 6-minute walk",
                    "interventionNames": [
                        "Diagnostic Test: Cardiac magnetic resonance image (CMR)",
                        "Diagnostic Test: Transthoracic Echocardiogram (TTE)",
                        "Diagnostic Test: Six-minute Walk Test"
                    ]
                },
                {
                    "label": "Healthy Control",
                    "description": "Subjects without history of cardiovascular diseases will have CMR, TTE, and 6-minute walk",
                    "interventionNames": [
                        "Diagnostic Test: Cardiac magnetic resonance image (CMR)",
                        "Diagnostic Test: Transthoracic Echocardiogram (TTE)",
                        "Diagnostic Test: Six-minute Walk Test"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "Cardiac magnetic resonance image (CMR)",
                    "description": "A magnetic resonance imaging study for assessment of cardiac structure and intracardiac flow",
                    "armGroupLabels": [
                        "Healthy Control",
                        "Light chain amyloidosis (AL) with cardiac involvement",
                        "Light chain amyloidosis (AL) without cardiac involvement",
                        "Transthyretin (ATTR) cardiac amyloidosis"
                    ]
                },
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "Transthoracic Echocardiogram (TTE)",
                    "description": "An imaging test that uses soundwaves that cannot be heard (ultrasound) to take pictures of the heart and vessels.",
                    "armGroupLabels": [
                        "Healthy Control",
                        "Light chain amyloidosis (AL) with cardiac involvement",
                        "Light chain amyloidosis (AL) without cardiac involvement",
                        "Transthyretin (ATTR) cardiac amyloidosis"
                    ]
                },
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "Six-minute Walk Test",
                    "description": "A self-paced, test of exercise capacity performed unencouraged intensity that measures the distance that patients can walk on a flat, hard surface in a period of 6 minutes",
                    "armGroupLabels": [
                        "Healthy Control",
                        "Light chain amyloidosis (AL) with cardiac involvement",
                        "Light chain amyloidosis (AL) without cardiac involvement",
                        "Transthyretin (ATTR) cardiac amyloidosis"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Define the intracardiac flow imaging biomarkers in cardiac amyloidosis (CA)",
                    "description": "Measured by cardiac magnetic resonance imaging (CMR)",
                    "timeFrame": "Baseline"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Subject is clinically stable without cardio-vascular-related hospitalizations within 6 weeks prior to enrollment as assessed by the investigators.\n* Subject is able to provide written informed consent and is willing and able to complete study procedures.\n* Currently in sinus rhythm by clinical assessment or documented electrocardiographic studies.\n* Subject and disease characteristics noted by medical record review:\n\n  * Healthy control volunteers must also meet the following criteria: Karnofsky performance scale \\> 80%; ECOG status 0 or 1.\n  * ATTR cardiac amyloidosis based on meeting all the following criteria: Diagnosis of amyloidosis within five years prior to study screening; Documentation of absence of AL, heavy chain disease, multiple myeloma or malignant lymphoproliferative disorders; Transthyretin amyloid deposits in cardiac tissue OR technetium (99mTc) pyrophosphate scintigraphy with grade 2 or 3 cardiac uptake OR Transthyretin amyloid deposits in non-cardiac tissue with echocardiographic evidence of cardiac involvement or an end-diastolic mean wall thickness \\>12mm OR Transthyretin amyloid deposits in non-cardiac tissue with CMR diagnostic of amyloidosis\n  * AL with cardiac involvement based on meeting all the following criteria: Diagnosis of amyloidosis within five years prior to study screening; Histopathologic diagnosis of amyloidosis with AL protein identification; Documented clinical signs or symptoms consistent with heart failure; Cardiac involvement as defined by: Amyloid deposits in cardiac deposits OR Echocardiography with an end-diastolic mean wall thickness \\> 12 mm in the absence of other causes OR Elevated NT-proBNP (\\>332 ng/L) in the absence of renal failure or atrial fibrillation OR CMR diagnostic of amyloidosis;\n  * AL without cardiac involvement based on meeting all the following criteria: Diagnosis of amyloidosis within five years prior to study screening; Histopathologic diagnosis of amyloidosis with AL protein identification; No documented clinical signs and symptoms consistent with heart failure from AL; Absence of cardiac involvement as defined by: Echocardiography with an end-diastolic mean wall thickness \\< 13 mm if the subject does not have other causes for increased wall thickness AND NT-proBNP \\<333 ng/L if the subject does not have renal failure or atrial fibrillation AND No CMR diagnostic of amyloidosis if CMR is available prior to screening.\n\nExclusion Criteria:\n\n* Unable to consent or unable to complete all study procedures.\n* Unable to ambulate for 6 minutes (confirmed at study coordinator visit).\n* Unable to maintain in supine position for 30 minutes.\n* Unable to maintain breath-holding for 10 seconds (confirmed at study coordinator visit).\n* Contraindications for safe CMR scanning (e.g., uncontrolled claustrophobia, cochlear implant, implanted neural stimulator).\n* Presence of implantable cardiac pacemaker or defibrillator.\n* History of complex congenital heart disease, intracardiac shunt (except for patent foramen ovale), prosthetic valves, prosthesis in the main pulmonary artery or ascending thoracic aorta.\n* Significant artifact from prior MRI studies.\n* Pregnant or breast-feeding women.\n* Weight equal to or greater than 155 kg.\n* Maximum body side-to-side or anterior-posterior diameter equal to or greater than 70 cm.\n* Documented non-sinus rhythm within 1 week prior to screening.\n* For healthy controls, the following exclusion criteria apply, confirmed per chart review and/or patient report:\n\n  * History of cardiomyopathy or structural heart disease;\n  * History of valvular disease of greater than mild severity;\n  * History of coronary artery disease or coronary heart disease;\n  * History of cardiac or thoracic surgery.\n  * History of symptomatic, persistent atrial tachyarrhythmia, ventricular tachyarrhythmia, or bradyarrhythmia;\n  * Left ventricular hypertrophy or abnormally increased myocardial thickness by prior echocardiography, cardiac computed tomography, or CMR;\n  * Acute kidney injury, OR chronic renal disease with glomerular filtration rate \\< 45 mL/min/1.73m\\^2 as per medical record review.\n  * Uncontrolled hypertension of systolic blood pressure \\> 150 mmHg or diastolic blood pressure \\> 90 mmHg as per medical record review;\n  * Taking three or more anti-hypertensive medications;\n  * Type 1 diabetes, OR uncontrolled type 2 diabetes mellitus of hemoglobin A1c greater than 8, as per medical record review;\n  * Taking three or more diabetic medications;\n  * History of confirmed stroke or transient ischemic attack, as per medical record review;\n  * Current cigarette smoker;\n  * History of plasma cell dyscrasia or chronic malignant hematologic diagnosis;\n  * BMI \\> 35 kg/m\\^2.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "40 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Patients with amyloidosis without and with cardiac involvement, and normal healthy volunteers",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Kathy Brown",
                    "role": "CONTACT",
                    "phone": "507-538-1321",
                    "email": "brown.kathy@mayo.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Ian C Chang, MD",
                    "affiliation": "Mayo Clinic",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Mayo Clinic",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kathy Brown",
                            "role": "CONTACT",
                            "phone": "507-538-1321",
                            "email": "brown.kathy@mayo.edu"
                        },
                        {
                            "name": "Ian C Chang, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Christopher Francois, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Mayo Clinic Clinical Trials",
                    "url": "https://www.mayo.edu/research/clinical-trials"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000686",
                    "term": "Amyloidosis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000057165",
                    "term": "Proteostasis Deficiencies"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4021",
                    "name": "Amyloidosis",
                    "asFound": "Amyloidosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M28747",
                    "name": "Proteostasis Deficiencies",
                    "relevance": "LOW"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}